Episode 57. ASH 2024 Update on Leukemia/Myeloid Neoplasms with Dr. Jayastu Senapati
Description
In this episode, we delve into the key clinically relevant abstracts in leukemia and myeloid neoplasms with Dr. Jayastu Senapati from the MD Anderson Cancer Center. Here are the links to the abstracts we discussed:
Older AML: Ven+HMA vs 7+3
Abstract 450: https://ash.confex.com/ash/2024/webprogram/Paper210320.html
Abstract 971: https://ash.confex.com/ash/2024/webprogram/Paper202801.html
Abstract 969: https://ash.confex.com/ash/2024/webprogram/Paper199267.html
Venetoclax resistance mechanisms
https://pubmed.ncbi.nlm.nih.gov/39478230/
FLAG-GO vs FLAG-IDA
CPX-351:
Abstract 55: https://ash.confex.com/ash/2024/webprogram/Paper207094.html
Abstract 60: https://ash.confex.com/ash/2024/webprogram/Paper200413.html
Menin Inhibitors
Abstract 211 https://ash.confex.com/ash/2024/webprogram/Paper194384.html
Abstract 212 https://ash.confex.com/ash/2024/webprogram/Paper207106.html
Abstract 213 https://ash.confex.com/ash/2024/webprogram/Paper194827.html
Abstracts 214 https://ash.confex.com/ash/2024/webprogram/Paper198218.html
Abstract 215 https://ash.confex.com/ash/2024/webprogram/Paper198218.html
Abstract 216 https://ash.confex.com/ash/2024/webprogram/Paper204375.html
FLT3 inhibitors
Abstract 221: https://ash.confex.com/ash/2024/webprogram/Paper201595.html
MDS
Abstract 349: https://ash.confex.com/ash/2024/webprogram/Paper194510.html
ATRA in MDS:
https://ash.confex.com/ash/2024/webprogram/Paper200433.html
United States
